Lantern Pharma Inc expected to post a loss of 48 cents a share - Earnings Preview
08/08/2025 13:58
Lantern Pharma Inc LTRN.OQ LTRN.O is expected to show no change in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2025 LSEG's mean analyst estimate for Lantern Pharma Inc is for a loss of 48 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Lantern Pharma Inc is $25.00, about 80% above its last closing price of $4.99 This summary was machine generated August 8 at 12:58 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments